Nama's AI scorecard currently rates Cooper Companies Buy (6.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is COO's P/E ratio?

Cooper Companies trades at a trailing price-to-earnings ratio of 13.5.

When does COO report earnings?

Cooper Companies's next scheduled report is on Dec 10, 2026. Analysts expect EPS of $1.07.

What is the COO price target?

The median analyst price target from 15 analysts is $65.00, with a range of $58.00 – $75.00.

Is COO Shariah compliant?

Nama's AAOIFI-style screen reads Cooper Companies as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Cooper Companies (COO)

Healthcare · Medical Instruments Supplies · NASDAQ

S&P 500

Cooper Companies (COO) is a Healthcare company in the Medical Instruments Supplies industry. It has a market capitalization of $11.86B, a trailing price-to-earnings ratio of 13.5 and a free-cash-flow yield of 3.5%. Over the most recent reported fiscal year, revenue grew 5.1% and free cash flow per share grew 50.8%. Nama's AI scorecard rates it Buy, 6.0 out of 10. On 12-month momentum it ranks in the trailing band of its market.

AI scorecard

Buy · 6.0/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Trailing · -20.6% over 12 months ex. last

Bottom 20% of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-44.5%

How far the last close sits under the highest price of the past five years.

Market cap	$11.86B
Trailing P/E	13.5
Price / book	1.4
Price / sales	2.8
FCF yield	3.5%
Dividend yield	—
Gross margin	65.9%
Operating margin	12.8%
Net margin	13.5%
Revenue growth (YoY)	+5.1%
Revenue growth (3-yr annual)	+7.3%
EPS growth (YoY)	+11.6%
FCF/share growth (YoY)	+50.8%
Beta	0.8
Exchange	NASDAQ
Sector	Healthcare
Industry	Medical Instruments Supplies

COO earnings

Next report: Dec 10, 2026 (Q4 2026, EPS estimate $1.07). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Sep 9, 2026	$1.15	$1.12	+2.7%	$1.07B
Q2 2026	Jun 4, 2026	$1.21	$1.09	+11.0%	$1.08B
Q1 2026	Mar 5, 2026	$1.10	$1.03	+6.8%	$1.02B
Q4 2025	Dec 4, 2025	$1.15	$1.11	+3.6%	$1.07B

COO analyst price target

Median target $65.00 from 15 analysts, ranging $58.00 – $75.00.

Medical Instruments Supplies peers

Ticker	Company	Market cap	P/E
ISRG	Intuitive Surgical	$159.96B	41.8
BDX	Becton, Dickinson	$57.71B	16.1
MDLN	Medline	$52.17B	25.1
ALC	Alcon	$36.23B	23.0
RMD	ResMed	$33.10B	20.4
WST	West Pharmaceutical Services	$27.85B	43.5
SOLV	Solventum	$15.38B	12.8
BAX	Baxter International	$13.34B	13.3

Explore live COO data on Nama Insights →

Recent Congressional trades

Cooper Companies trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Alan Armstrong	Senate	Buy	$1,001 - $15,000	Jul 21, 2026
Gilbert Cisneros	House	Buy	$1,001 - $15,000	Jan 12, 2026

COO FAQ

Is COO a buy?: Nama's AI scorecard currently rates Cooper Companies Buy (6.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is COO's P/E ratio?: Cooper Companies trades at a trailing price-to-earnings ratio of 13.5.
When does COO report earnings?: Cooper Companies's next scheduled report is on Dec 10, 2026. Analysts expect EPS of $1.07.
What is the COO price target?: The median analyst price target from 15 analysts is $65.00, with a range of $58.00 – $75.00.
Is COO Shariah compliant?: Nama's AAOIFI-style screen reads Cooper Companies as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.